American Journal of Hematology · 2011 · 35 citations · 11 references
MedicineHematologyOncologyChemotherapyClinical PharmacologyHematologic OncologyChemotherapy In Hematologic MalignanciesDose Adjustment In OncologyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyHematologic ToxicityHematologic Toxicity ManagementAcute Leukemia ChemotherapyAcute LeukemiasAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentCytarabine-based RegimensFractionated DosingFractionated TreatmentPulmonary Veno-occlusive Disease
This Phase 1/2 study aimed to determine optimal doses of daunorubicin (DNR; mg/m(2)) and cytarabine (mg/m(2)) to be combined with fractionated doses of gemtuzumab ozogamicin (GO, Mylotarg(®); 3 mg/m(2) on day 1, 4, and 7) satisfying safety requirements. Three dose levels of DNR/AraC were investigated namely (45, 100), (60, 100), and (60, 200). Patients included were acute myeloid leukemia in first relapse, aged 50-70 years. Hematological recovery was 31 days for neutrophil and 32 days for platelet counts. A documented infectious episode > Grade 2 occurred in 11/20 patients (55%). None of the 20 patients had signs of veno-occlusive disease. Overall, eleven patients reached complete remission (CR), two CR with incomplete platelets recovery. The results showed that combination of fractionated GO doses with DNR at 60 mg/m(2)/d for 3 days and cytarabine at 200 mg/m(2)/d for 7 days is tolerable and could be further investigated in the front-line therapy.
11
Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations
Medicine, Hematology, Oncology +17
Alan K. Burnett, Robert K. Hills, Donald Milligan et al. · Journal of Clinical Oncology · 2010 · 652 citations · Full text
Medicine, Oncology, Pharmacology +17
Vincent H. J. van der Velden, Jeroen G. te Marvelde, Patricia G. Hoogeveen et al. · Blood · 2001 · 338 citations
Medicine, Oncology, Pharmacology +17